p21WAF1/CIP1 gene transcriptional activation exerts cell growth inhibition and enhances chemosensitivity to cisplatin in lung carcinoma cell
- Junxia Wei,
- Jiang Zhao†2,
- Min Long†1,
- Yuan Han1,
- Xi Wang1,
- Fang Lin1,
- Jihong Ren1,
- Ting He1 and
- Huizhong Zhang1Email author
© Wei et al; licensee BioMed Central Ltd. 2010
Received: 10 November 2009
Accepted: 19 November 2010
Published: 19 November 2010
Non-small-cell lung carcinomas (NSCLCs) exhibit poor prognosis and are usually resistant to conventional chemotherapy. Absence of p21WAF1/CIP1, a cyclin-dependent kinase (cdk) inhibitor, has been linked to drug resistance in many in vitro cellular models. RNA activation (RNAa) is a transcriptional activation phenomena guided by double-strand RNA (dsRNA) targeting promoter region of target gene.
In this study, we explored the effect of up-regulation of p21 gene expression on drug-resistance in A549 non-small-cell lung carcinoma cells by transfecting the dsRNA targeting the promoter region of p21 into A549 cells.
Enhanced p21 expression was observed in A549 cells after transfection of dsRNA, which was correlated with a significant growth inhibition and enhancement of chemosensitivity to cisplatin in A549 cells in vitro. Moreover, in vivo experiment showed that saRNA targeting the promoter region of p21 could significantly inhibit A549 xenograft tumor growth.
These results indicate that p21 plays a role in lung cancer drug-resistance process. In addition, this study also provides evidence for the usage of saRNA as a therapeutic option for up-regulating lower-expression genes in lung cancer.
Lung cancer is the most common cause of cancer mortality worldwide. Non-small-cell lung carcinomas (NSCLCs), which represent around 80% of lung tumors, exhibit poor prognosis and are usually resistant to conventional chemotherapy. Cisplatin is one of the most potent anticancer agents, displaying significant clinical activity against a variety of solid tumors. The most effective systemic chemotherapy for non-small cell lung cancer (NSCLC) was cisplatin-based combination treatment. Unfortunately, the outcome of cisplatin therapy on NSCLC seems to be unsatisfactory. The use of cisplatin in cancer chemotherapy is limited by acquired or intrinsic resistance of cells to the drug. The cytotoxicity of cisplatin is believed mainly due to interaction with DNA, forming inter-and intra-strand adducts, hindering both RNA transcription and DNA replication, leading to cell cycle arrest and apoptosis. Numerous cellular mechanisms potentially contributing to clinical cisplatin resistance have been proposed, including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts but the precise mechanisms are still need to be validated. It has been reported that P21 expression level is involved in the resistant phenotype of this drug [1–4].
p21WAF1/CIP1 (p21) is a well-characterized cyclin-dependent kinase (cdk) inhibitor that belongs to the Cip/Kip family of cdk inhibitors. It mainly inhibits the activity of cyclin/cdk2 complexes and negatively modulates cell cycle progression [3–6]. Loss or inactivation of p21 is seen clinically in primary solid tumors and related with poor prognosis of these tumors [7, 8]. Additionally, there is a growing body of evidence suggesting that functional loss of p21 can mediate a drug-resistance phenotype in tumor therapy [9, 10].
RNA-induced gene activation is a transcriptional gene activation phenomenon specifically induced by double small RNA (dsRNA) molecule targeting gene promoter regions. This phenomenon was termed RNAa and the dsRNA molecules were designated small activating RNAs (saRNAs). By targeting gene promoter regions, saRNAs induce the demethylation of histone, leading to transcriptional gene activation. It has been demonstrated that saRNA could inhibit cell proliferation and viability via up-regulation of p21 and E-cadherin in human bladder cancer cells [11–13]. Since saRNAs offer a practical and cost-effective approach to activate gene expression, it may be additional method except for ectopic expression in enhancing expression of targeted genes.
In this study, we explored the effect of up-regulation of p21 gene expression on drug-resistance in A549 non-small-cell lung carcinoma cells by transfecting the saRNA targeting the promoter region of p21 into A549 cells. We observed activation of p21 expression in A549 lung carcinoma cells after transfection of saRNA. The enhanced p21 expression was correlated with a significant growth inhibition and enhancement of chemosensitivity to cisplatin in A549 cells in vitro and vivo. These results provide evidence of an additional therapeutic strategy for lung cancer therapy especially for chemoresisitance lung carcinomas.
Design and preparation of dsRNA
saRNA targeting the promoter of p21 at position-322 relative to the transcription start site was termed as dsP21-322 and designed as previously described . Scramble dsRNA with the following sequence: S, 5'-UUCUCCGAACGUGUCACGU [dT][dT]-3'; AS, 5'-ACGUGACACGUUCGGAGAA[dT][dT]-3' was also synthesized and used as control. Synthetic dsRNAs were manufactured by Genepharma Inc (Shanghai, China).
Cell culture and transfection
Human lung carcinoma cells (A549) were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum and penicillin (100 Units/ml)/streptomycin(0.1 mg/ml) in 5% CO2 incubator at 37°C. Cells were seeded into six-well plates with growth medium at a density of 0.8 × 105 cells/well respectively and cultured overnight to (30-50)% confluence prior to transfection. Cells were then transfected with 100 pmol/well of dsP21-322 or scramble dsRNA, respectively, using the LipofectamineTM2000 reagent (Invitrogen, USA) according to the manufacturer's protocols.
RNA isolation and semi-quantitative RT-PCR
Total RNAs were extracted from dsP21-322, scramble dsRNA and mock transfected A549 cells by using TRIzol reagent according to the manufacturer's instructions. Complementary DNA (cDNA) was generated from total RNA by reverse transcription using moloney murine leukemia virus (M-MLV). PCR amplification of the cDNA was performed in a reaction mixture with a final volume of 30 μL containing 2 μL of 4 × dNTPs, one unit of Taq DNA polymerase, and 10 mmol/L of each paired primer specific to p21 gene. The primers used for RT-PCR of p21 were forward primer, 5'-TTGATTAGCAGCGGAACA-3' and reverse primer, 5'-TACAGTCTAGGTGGAGAAACG-3'.
The cells from experiment group and control groups were harvested and washed with PBS (pH 7.4) twice and resuspended in lysis buffer (1 mM dithiothreitol, 0.125 mM EDTA, 5% glycerol, 1 mM phenylmethylsulfonylfluoride, 1 μg/mL leupeptin, 1 μg/mL pepstatin, 1 μg/mL aprotinin, 1% Triton X-100 in 12.5 mM Tris-HCl buffer, pH 7.0) on ice. The cell extracts were clarified by centrifugation and the protein concentrations were determined by using the Bio-Rad protein assay kit (Bio-Rad, Hercules, CA). Each protein extract (25 μg) was electrophoresed on a 12% SDS-polyacrylamide gel, transferred to PVDF membrane in a buffer containing 25 mM Tris-HCl (pH 8.3), 192 mM glycine, 20% (v/v) methanol, and blocked in 5% (w/v) skimmed milk in Tris buffered saline-Tween 20 (0.1% by volume, TBST) for 1 hour at room temperature, and probed with specific primary antibodies overnight at 4°C. Then primary antibodies were removed and the blots were extensively washed with TBST for three times. Blots were then incubated for an hour at room temperature with the secondary antibodies (goat anti-rabbit/mouse antibody coupled to horseradish peroxidase, 1:3000 dilution) in 1% (w/v) skimmed milk dissolved in TBST. Following removal of the secondary antibody, blots were extensively washed as above for an hour and developed using the Enhanced Chemiluminescence Kit (NENTM Life Science Products Inc, Boston, MA). The primary antibodies used in this experiment for western blotting analysis were anti-p21 (1:100, Santa Cruz) and anti-β-actin (1:500, Sigma) antibody.
2.5 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-diphenyl-2Htetrazolium bromide (MTT) assay
MTT assay was performed to assess the effect of p21 expression on cell proliferation. Transiently transfected lung carcinoma cells were plated in 96-well plate at a density of 3.0 × 103 cells/well for proliferation assay. Then for 5 days, every 24 h a batch of cells were stained with 20 μl sterile MTT dye (5 mg/ml; Sigma, USA) at 37°C for 4 h, then culture medium was removed and 150 μl of DMSO was added and thoroughly mixed in for 10 min. Spectrometric absorbance at 490 nm was measured by using a microplate reader. All experiments were performed in triplicate.
Colony formation assay
Approximately 0.5 × 103 A549 cells transiently transfected with dsP21-322, scramble dsRNA and mock were plated in 100-mm culture dishes, respectively. After 18 days, cells were fixed with methanol and stained with 0.1% crystal violet. Visible colonies were manually counted.
Flow cytometric analysis of apoptosis
An annexin V-fluorescein isothiocyanate apoptosis detection kit (Zymed, USA) was used to detect cell apoptosis. Approximately 1 × 106 A549 cells transiently transfected with dsP21-322, scramble dsRNA and mock, respectively, were harvested and analyzed by Flow Cytometry (BD, USA).
In vitro chemosensitivity assay
The dsP21-322, scramble dsRNA and mock transfected A549 cells were seeded in 96-well plate at a density of 5 × 104 cells/well. The cells were then treated with 5 μg/ml cisplatin for 48 h.Then, 20 μl of MTT stock solution (5 mg/ml) was added to each well, and the cells were incubated at 37°C for 4 h. The supernatant was replaced with DMSO to dissolve formazan production. The A490 nm values were assayed in a microplate reader. The ratio of the absorbance of treated cells relative to that of the control cells was calculated and expressed as a percentage of cell viability. The mean of three parallel samples was calculated. Experiments were performed in triplicate and standard deviations were calculated based on the average of three experiments.
In vivo chemosensitivity assay
A549 cells (1 × 106) were injected subcutaneously into the right posterior limb of BALB/c nude mice (4-6 weeks old). When palpable tumors (about 100-130 mm3) arose within 16-21 days, mice were randomized to treatment and control groups. Three groups (five mice each) received intratumoral injections of mixture of 30 μg of LipofectamineTM2000-encapsulated dsP21-322, scramble dsRNA and PBS respectively, every 3 days for 3 weeks. The other two groups received intratumoral injection of PBS combined with cisplatin or dsP21-322 combined with 5 mg/kg cisplatin, individually, every 3 days for 3 weeks. Tumor growth was monitored by caliper-measuring two perpendicular tumor diameters every 3 days, and the volume of the tumor was calculated from the formula: V = (width2 × length × 0.5). At the end of the experiment, tumor weight was assessed by sacrificing the mice, and by removing and weighing the tumor. Animal experiments in this study were carried out in accordance with the medicine institutional guidelines of Fourth Military Medical University.
Immunohistochemistry of tumors
The sections of the tumor tissues embedded in paraffin were stained using mouse anti-p21 antibody (Santa Cruz) at 1:50 dilution overnight at 4°C. After brief washing, all slides were stained and visualized with a Histofine SAB-PO(M) kit (Nichirei, Tokyo, Japan) according to the manufacturer's instructions.
Results were expressed as Means ± standard deviation (SD). Statistical analyses were performed using SPSS statistical software. Student's t-test and one-way analysis of variance (ANOVA) followed by Dunnett's multiple comparison tests were adopted. Values of p < 0.05 were considered as significant and indicated by asterisks in the figures.
P21 was up-regulated by saRNA in A549 cell line
Lung carcinoma cell proliferation and colony formation were inhibited by p21 up-regulation in vitro
The effect of up-regulation of p21 gene expression on the cell cycle
The specific up-regulation of p21 gene expression enhances cisplatin cytotoxicity in vitro
The effect of P21 up-regulation on chemosensitivity to cisplatin in vivo
Lung cancer is considered usually to acquire resistance to chemotherapy during multiple courses of therapy, which leads to poor prognosis, compared with other types of human malignancies. Thus, attempts at improving the survival of patients affected by this disease depend largely on strategies targeting development of tumor cell resistance to chemotherapy drugs, which cannot be rationally planned without a detailed knowledge of the mechanisms underlying this phenomenon. Searching for molecular targets participating in the process of drug-resistance and utilizing these targets to oppose drug-resistance in chemotherapy will be beneficial to the clinical therapy. There is evidence that alteration of CDK inhibitors in cancer may affect the response to chemotherapeutic treatment. Loss expression of p21 has been linked to drug-resistance in many in vitro cellular models. However, to date, evidence about the relationship between this CDK inhibitor and lung carcinoma drug-resistance has been lacking.
It has been reported that genetic and epigenetic abnormalities can induce lower expression of p21, which is linked to chemoresistance in many in vitro cellular models . Colon cancer cells with deletions of p21WAF1/CIP1 showed abnormal response to treatment with doxorubicin, which is due to abnormal block to G2 decreases undergoing mitosis of cell . It was also demonstrated that forced overexpression of p21WAF1/CIP1 in osteosarcoma cells increased sensitivity to chemotherapeutic agents and leaded to G1 and G2/M arrest [20, 21]. These results indicate that deletion or lower expression of p21 is involved in drug-resistance. Various mechanisms exist to regulate the levels of p21 in a cell including transcriptional regulation, epigenetic silencing, mRNA stability, and ubiquitin-dependent and-independent degradation of the protein . The dsRNA used in RNAa study was designed by closely following rational siRNA design rules and avoided CpG-rich islands. These characteristics may direct the modification of histone and further the activation or silencing of target gene . Cisplatin have been used as first-line therapy to treat lung carcinoma, but its curative effect is far from satisfactory. Thus, in order to improve the prognosis of patients with type of refractory cancer, it is necessary to identify and target genes which conduce to the treatment of lung carcinoma, such as enhancement of conventional chemotherapy.
In this study, we elevated the expression of p21 in lung carcinoma A549 cells by using saRNA targeting the promoter region of p21, which has been demonstrated to transcriptionally activate the expression of p21 gene. We detected up-regulation of p21 after tranfection of saRNA compared with scrambled dsRNA in A549 cells, the results showed that the expression of p21 could be increased in lung cancer cells by saRNA transfection.
To explore the phenotype changes induced by p21 up-regulation in A549 cells, we detected the proliferation, colony formation, apoptosis and cell cycle change of saRNA transfected cells. The results showed that up-regulation of p21 by transcriptional activation inhibited the proliferation and colony formation of lung cancer cells. Cell cycle analysis showed that endogenous p21 up-regulation induced cell accumulation both in the G1/G0 phase in lung cancer cells, which leads to proliferation inhibition of lung cancer cells, but there was no apoptosis cells detected after dsP21-322 transfection. It was reported that p21 plays dual roles as both as pro and anti-apoptotic gene. Whether p21 exhibits pro or anti-apoptotic effects is likely to depend on the specific cellular context . In our study, we did not detect obviously difference in apoptotic rates between dsP21-322 transfected cells and scramble dsRNA transfected cells. These data indicated that activation of p21 expression inhibited the proliferation and enhanced chemosensitivity to cisplatin by process unrelated with apoptotic pathway. Then, we detected the chemosensitivity of saRNA transfected A549 cells to cisplatin in vitro, the results showed that up-regulation of p21 obviously enhanced the sensitivity of A549 cells to cisplatin in vitro. Although we did not find the precise mechanism of this phenomenon, further studies are needed to clarify the accrual role of p21 up-regulation to chemosensitivity of cisplatin. We observed that chemosensitivity of dsP21-322 transfected A549 cells to paclitaxel also increased comparing with control group. Chemotherapy with combination of platinum drug and paclitaxel is a relative effective strategy in non-small-cell lung carcinomas therapy. Enhancement of chemosensitivity to both cisplatin and paclitaxel (Additional file 1, Figure S1) indicates that it is due to their crossing in the signal pathways for the chemotherapeutic effect. Since the up-regulation of p21 gene expression exerts profound effects on cell growth and enhances chemosensitivity to cisplatin, we explored the therapeutic role of p21 in combination with cisplatin in animal models. We observed that tumor growth was inhibited more obviously in the group treated with dsP21-322 combining with cisplatin than those treated with PBS or scramble dsRNA with cisplatin. In this study, as reported on other human malignancies, results from chemosensitivity tests showed that the RNAa-mediated up-regulation of p21 gene expression synergistically enhanced the cytotoxicity of cisplatin both in vitro and in vivo, which made us believe that cisplatin chemotherapy could be more effective in combination with RNAa-mediated up-regulation of p21 gene expression.
In summary, this study demonstrates that up-regulating expression of p21 in lung cancer by RNAa technique can inhibit proliferation, enhance chemotherapeutic sensitivity to cisplatin in vitro and vivo, which may significantly contribute to therapy of lung cancer, especially for drug-resistance tumor therapy.
This study was supported by grant from National Natural Science Foundation of China (30772181).
- Rosell R, Felip E: Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. Semin Oncol. 2001, 28: 37-44. 10.1016/S0093-7754(01)90058-2.View ArticlePubMedGoogle Scholar
- Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L: Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer. Ai Zheng. 2004, 23: 845-850.PubMedGoogle Scholar
- Stordal B, Davey M: Understanding cisplatin resistance using cellular models. IUBMB Life. 2007, 59: 696-699. 10.1080/15216540701636287.View ArticlePubMedGoogle Scholar
- Kartalou M, Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res. 2001, 478: 23-43.View ArticlePubMedGoogle Scholar
- Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA: Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation. Proc Natl Acad Sci USA. 1999, 96: 1002-1007. 10.1073/pnas.96.3.1002.View ArticlePubMedPubMed CentralGoogle Scholar
- Gartel AL, Tyner AL: The growth-regulatory role of p21 (WAF1/CIP1). Prog Mol Subcell Biol. 1998, 20: 43-71.View ArticlePubMedGoogle Scholar
- Sharpless NE, DePinho RA: Telomeres, stem cells, senescence, and cancer. J Clin Invest. 2004, 113: 160-168.View ArticlePubMedPubMed CentralGoogle Scholar
- Mooi WJ, Peeper DS: Oncogene-induced cell senescence-halting on the road to cancer. N Engl J Med. 2006, 355: 1037-1046. 10.1056/NEJMra062285.View ArticlePubMedGoogle Scholar
- Cariou S, Donovan JC, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM: Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells. Proc Natl Acad Sci USA. 2000, 97: 9042-9046. 10.1073/pnas.160016897.View ArticlePubMedPubMed CentralGoogle Scholar
- Giannakakou P, Robey R, Fojo T, Blagosklonny MV: Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity. Oncogene. 2001, 20: 3806-3813. 10.1038/sj.onc.1204487.View ArticlePubMedGoogle Scholar
- Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R: Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci USA. 2006, 103: 17337-17342. 10.1073/pnas.0607015103.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen Z, Place RF, Jia ZJ, Pookot D, Dahiya R, Li LC: Antitumor effect of dsRNA-induced p21WAF1/CIP1 gene activation in human bladder cancer cells. Mol Cancer Ther. 2008, 7: 698-703. 10.1158/1535-7163.MCT-07-2312.View ArticlePubMedGoogle Scholar
- Yang K, Zheng XY, Qin J, Wang YB, Bai Y, Mao QQ, Wan Q, Wu ZM, Xie LP: Up-regulation of p21WAF1/Cip1 by saRNA induces G1-phase arrest and apoptosis in T24 human bladder cancer cells. Cancer Lett. 2008, 265: 206-214. 10.1016/j.canlet.2008.02.014.View ArticlePubMedGoogle Scholar
- Niculescu AB, Chen X, Smeets M, Hengst L, Prives C, Reed SI: Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol. 1998, 18: 629-643.View ArticlePubMedPubMed CentralGoogle Scholar
- Ogryzko VV, Wong P, Howard BH: WAF1 retards Sphase progression primarily by inhibition of cyclindependent kinases. Mol Cell Biol. 1997, 17: 4877-4882.View ArticlePubMedPubMed CentralGoogle Scholar
- Radhakrishnan SK, Feliciano CS, Najmabadi F, Haegebarth A, Kandel ES, Tyner AL: Constitutive expression of E2F-1 leads to p21-dependent cell cycle arrest in S phase of the cell cycle. Oncogene. 2004, 23: 4173-4176. 10.1038/sj.onc.1207571.View ArticlePubMedGoogle Scholar
- McDonald ER, Wu GS, Waldman T, El-Deiry WS: Repair defect in p21 WAF1/CIP12/2 human cancer cells. Cancer Res. 1996, 56: 2250-2255.PubMedGoogle Scholar
- Abde MA, Ben HP: p21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008, 10: e19-10.1017/S1462399408000744.View ArticleGoogle Scholar
- T Waldman C, Lengaue KW, Kinzler B, Vogelstein B: Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature. 1996, 381: 713-716. 10.1038/381713a0.View ArticleGoogle Scholar
- Li WW, Fan J, Hochhauser D, Bertino JR: Overexpression of p21waf1 leads to increased inhibition of E2F-1 phosphorylation and sensitivity to anticancer drugs in retinoblastoma-negative human sarcoma cells. Cancer Res. 1997, 57: 2193-2199.PubMedGoogle Scholar
- Medema RH, Klompmaker R, Smits VA, Rijksen G: p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene. 1998, 16: 431-441. 10.1038/sj.onc.1201558.View ArticlePubMedGoogle Scholar
- Gartel AL, Radhakrishnan SK: Lost in Transcription: p21 Repression, Mechanisms, and Consequences. Cancer Res. 2005, 65: 3980-3985. 10.1158/0008-5472.CAN-04-3995.View ArticlePubMedGoogle Scholar
- Liu SX, Robert Bishop W, Liu M: Differential effects of cell cycle regulatory protein p21WAF1/Cip1 on apoptosis and sensitivity to cancer chemotherapy. Drug Resistance Updates. 2003, 6: 183-195. 10.1016/S1368-7646(03)00044-X.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/632/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.